Evidence map›Paper›PMID 42542640›Full record

ArticleJournal of migration and health2026

Design and results of a pilot community screening strategy for hepatitis B and hepatitis C to promote early access to treatment among migrant populations from high-prevalence countries residing in Catalonia (MiCatC).

Venus Forero, Sandra Manzanares-Laya, Hakima Ouaarab, Prat Jordi Gómez I, Anna Not, Marcos Montoro, Esteve Muntada, Jordi Casabona, Elisa Martró, Mayara Torres and 5 more

Abstract read
In one paragraph

Article in Journal of migration and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Venus ForeroSub directorate General of Addictions, HIV, STI and Viral Hepatitis, Public Health Agency of Catalonia (Gencat), Barcelona, Spain.
Sandra Manzanares-LayaSub directorate General of Addictions, HIV, STI and Viral Hepatitis, Public Health Agency of Catalonia (Gencat), Barcelona, Spain.
Hakima OuaarabEquip de Salut Pública i Comunitària (ESPIC), Unitat de Salut Internacional Drassanes-Vall d'Hebron, Barcelona.
Prat Jordi Gómez IEquip de Salut Pública i Comunitària (ESPIC), Unitat de Salut Internacional Drassanes-Vall d'Hebron, Barcelona.
Anna NotServicio de Microbiología, Laboratori Clínic Metropolitana Nord (LCMN), Hospital Universitari i Institut d'Investigació Germans Trias i Pujol, Badalona.
Marcos MontoroCentre d'Estudis Epidemiològics sobre les ITS i la Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya (ASPCAT), Badalona.
Esteve MuntadaCentre d'Estudis Epidemiològics sobre les ITS i la Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya (ASPCAT), Badalona.
Jordi CasabonaCentre d'Estudis Epidemiològics sobre les ITS i la Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya (ASPCAT), Badalona.
Elisa MartróServicio de Microbiología, Laboratori Clínic Metropolitana Nord (LCMN), Hospital Universitari i Institut d'Investigació Germans Trias i Pujol, Badalona.
Mayara TorresSub directorate General of Addictions, HIV, STI and Viral Hepatitis, Public Health Agency of Catalonia (Gencat), Barcelona, Spain.
María Serrano GregoriSub directorate General of Addictions, HIV, STI and Viral Hepatitis, Public Health Agency of Catalonia (Gencat), Barcelona, Spain.
Manuel Gómez-BarreraPharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid.
Raquel Domínguez-HernándezPharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid.
Xavier MajóSub directorate General of Addictions, HIV, STI and Viral Hepatitis, Public Health Agency of Catalonia (Gencat), Barcelona, Spain.
Joan ColomSub directorate General of Addictions, HIV, STI and Viral Hepatitis, Public Health Agency of Catalonia (Gencat), Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The elimination of hepatitis C virus (HCV) and hepatitis B virus (HBV) requires strategies to overcome barriers associated with access to healthcare among migrants. The objective was to design and implement a community-screening-strategy (MiCat) for HBV and HCV among migrant populations from high-prevalence countries residing in Catalonia. Methodology: A pilot community-screening was conducted in religious sites, associations or community centres. A multidisciplinary team consisting of peer educators, community health agents, and nurses was established. interventions consisted of workshops pertaining to viral hepatitis, rapid tests featuring onsite results and the collection of dried blood samples for HCV RNA test if anti-HCV-positive result. HBsAg-positive and/or HCV-RNA-positive participants were contacted and referred for hepatology. Results: A total of 1,505 people (71% men; 68% Pakistani) were screened over 10 months. Of the total, 71% were long-term residents in Catalonia (>5 years). The history of exposure was more common among women. A total of individuals tested, 3% (95% CI 2.2-4.0) (n=44) were HBsAg-positive (91% men; 33% new diagnoses), 36.4% (n=16) referred to hepatology (33% women) and 2 treated; and a 3.3% (95% CI 2.42-4.28) (n=49) were anti-HCV-positive (84% men), of these 32.6% (n=16) were HCV-RNA-positive (1.06% viremia prevalence; all new diagnoses), 13 patients completed the treatment. Conclusions: MiCatC project was able to detect, link to care and treat migrant population from countries with high prevalence of HCV and/or HBV based on a multidisciplinary team including community assets. It is essential to include the gender perspective to ensure that migrant women with hepatitis can receive specialised care.

Indexed as

community screeningHepatitis B virushepatitis C virusinterventionmigrant

Identifiers

PMID42542640
PMCPMC13427673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.